Cisplatin-incorporated nanoparticles of poly(acrylic acid-co-methyl methacrylate) copolymer

Background Although cisplatin is extensively used in the clinical field, its intrinsic toxicity limits its clinical use. We investigated nanoparticle formations of poly(acrylic acid-co-methyl methacrylate) (PAA-MMA) incorporating cisplatin and their antitumor activity in vitro and in vivo. Methods Cisplatin-incorporated nanoparticles were prepared through the ion-complex formation between acrylic acid and cisplatin. The anticancer activity of cisplatin-incorporated nanoparticles was assessed with CT26 colorectal carcinoma cells. Results Cisplatin-incorporated nanoparticles have small particle sizes of less than 200 nm with spherical shapes. Drug content was increased according to the increase of the feeding amount of cisplatin and acrylic acid content in the copolymer. The higher acrylic acid content in the copolymer induced increase of particle size and decrease of zeta potential. Cisplatin-incorporated nanoparticles showed a similar growth-inhibitory effect against CT26 tumor cells in vitro. However, cisplatin-incorporated nanoparticles showed improved antitumor activity against an animal tumor xenograft model. Conclusion We suggest that PAA-MMA nanoparticles incorporating cisplatin are promising carriers for an antitumor drug-delivery system.

[1]  H. Maeda Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Chengmeng Jin,et al.  Developing a Highly Stable PLGA-mPEG Nanoparticle Loaded with Cisplatin for Chemotherapy of Ovarian Cancer , 2011, PloS one.

[3]  A. Boddy,et al.  A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours , 2011, British Journal of Cancer.

[4]  Robert Gurny,et al.  Drug-loaded nanoparticles : preparation methods and drug targeting issues , 1993 .

[5]  B. Rosenberg Platinum Complexes for the Treatment of Cancer , 1978 .

[6]  Y. Sugiyama,et al.  Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. , 2003, Cancer research.

[7]  T. Boulikas,et al.  Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. , 2005, Oncology reports.

[8]  G. Cassali,et al.  Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity , 2012, International journal of nanomedicine.

[9]  David J. Yang,et al.  Formation and Characterization of Cisplatin-Loaded Poly(benzyl 1-glutamate) Microspheres for Chemoembolization , 1994, Pharmaceutical Research.

[10]  N. Nishiyama,et al.  Cisplatin‐incorporated Polymeric Micelles Eliminate Nephrotoxicity, While Maintaining Antitumor Activity , 2001, Japanese journal of cancer research : Gann.

[11]  Shin Jung,et al.  Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. , 2008, Journal of pharmaceutical sciences.

[12]  R. Gemeinhart,et al.  Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[13]  N. Nitta,et al.  Prospective, randomized, fellow eye comparison of WaveLight® Allegretto Wave® Eye-Q versus VISX CustomVueTM STAR S4 IRTM in photorefractive keratectomy: analysis of visual outcomes and higher-order aberrations , 2011, Clinical ophthalmology.

[14]  F. Bressolle,et al.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review , 2004, Cancer Chemotherapy and Pharmacology.

[15]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.

[16]  F. Trotta,et al.  PREPARATION AND CHARACTERIZATION OF , 1996 .